title: The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view.
abstract: Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. The pathogenesis of CAD relates to the presence of atherosclerotic plaques in the coronary arteries, which are most frequently treated today by percutaneous coronary intervention. Small vessel disease treatment represents one-third of all percutaneous coronary interventions with higher rates of restenosis and major adverse cardiac events. Initially, drug-eluting stents (DES) were developed to reduce in-stent restenosis, improving clinical outcomes and reducing the need for target vessel revascularization. However, late and very late stent thrombosis emerged as a new problem compromising DES's long-term results. The cobalt-chromium everolimus-eluting stent (CoCr-EES) represents the results of an evolutionary process in DES technology aimed at improving the shortcomings of first-generation DES. Small vessel CAD has historically been an obstacle to long-term patency following implantation of DES. Antirestenotic efficacy has been shown to be of high relevance in small vessels. Therefore, stent selection may play an important role in determining outcomes in this subgroup of patients. This article will review the performance of CoCr-EES in the treatment of small vessel CAD from preclinical, clinical, and pathology perspectives, and it will highlight the most important findings in this regard.
authors.affiliation: CVPath Institute, Inc., Gaithersburg, MD, USA.
authors.forename: Oscar D
authors.initials: OD
authors.lastname: Sanchez
authors.affiliation: CVPath Institute, Inc., Gaithersburg, MD, USA.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Yahagi
authors.affiliation: CVPath Institute, Inc., Gaithersburg, MD, USA.
authors.forename: Tobias
authors.initials: T
authors.lastname: Koppara
authors.affiliation: CVPath Institute, Inc., Gaithersburg, MD, USA.
authors.forename: Renu
authors.initials: R
authors.lastname: Virmani
authors.affiliation: CVPath Institute, Inc., Gaithersburg, MD, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Joner
keywords: Xience V; cobalt–chromiun everolimus-eluting stent; pathology; small vessel